Cutting back on sleep drastically reduces a healthy young man’s testosterone levels, according to a study published in the June 1 issue of the Journal of the American Medical Association (JAMA).

Eve Van Cauter, PhD, professor in medicine and director of the study, found that men who slept less than five hours a night for one week in a laboratory had significantly lower levels of testosterone than when they had a full night’s sleep. Low testosterone has a host of negative consequences for young men, and not just in sexual behavior and reproduction. It is critical in building strength and muscle mass, and bone density.

“Low testosterone levels are associated with reduced well being and vigor, which may also occur as a consequence of sleep loss” said Van Cauter.

At least 15% of the adult working population in the US gets less than 5 hours of sleep a night, and suffers many adverse health effects because of it. This study found that skipping sleep reduces a young man’s testosterone levels by the same amount as aging 10 to 15 years.

“As research progresses, low sleep duration and poor sleep quality are increasingly recognized as endocrine disruptors,” Van Cauter said.

The ten young men in the study were recruited from around the University of Chicago campus. They passed a rigorous battery of tests to screen for endocrine or psychiatric disorders and sleep problems. They were an average of 24 years old, lean and in good health.

For the study, they spent three nights in the laboratory sleeping for up to ten hours, and then eight nights sleeping less than five hours. Their blood was sampled every 15 to 30 minutes for 24 hours during the last day of the ten-hour sleep phase and the last day of the five-hour sleep phase.

The effects of sleep loss on testosterone levels were apparent after just one week of short sleep. Five hours of sleep decreased their testosterone levels by 10% to 15%. The young men had the lowest testosterone levels in the afternoons on their sleep restricted days, between 2 pm and 10 pm.

The young men also self-reported their mood and vigor levels throughout the study. They reported a decline in their sense of well-being as their blood testosterone levels declined. Their mood and vigor fell more every day as the sleep restriction part of the study progressed.

Testosterone levels in men decline by 1% to 2% a year as they age. Testosterone deficiency is associated with low energy, reduced libido, poor concentration, and fatigue.

Article Source: http://www.eurekalert.org/pub_releases/2011-05/uocm-sll053111.php

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/bostontestosterone
855-617-MEDS (6337)

Call Boston Testosterone Partner s to learn more about our FDA approved Second Generation HGH releasing peptide therapy.

We are the Nation’s foremost medical experts in HGH optimization through the use of prescription Sermorelin GHRP2 & GHRP6! Importantly, we are also the only Men’s Hormone Clinic that requires our pharmacies to send out Laboratory Analysis Reports with every Rx to every patient.

Far superior technology than any other Sermorelin product available in the US. See the difference with BTP.

Eliminate Cellulite

Increase Energy

Increase Mood and Memory

Increase Lean Muscle Mass

Reduce Body Fat

Improve Skin Tone

Lower Blood Pressure

Improve Cholesterol levels

Improve Kidney Function

At Boston Testosterone, our state-of-the-art compounding pharmacy has focused their considerable knowledge on producing a product that delivers greater benefits to the patient at a price that is more affordable than HGH. This exciting, new product, SERMORELIN GHRP2, has proven to be much more effective and have a more profound effect on body composition.

When we’re young, our bodies produce a growth hormone releasing factor that triggers our pituitary gland to produce and release human growth hormone (hGH) in levels that are sufficient to sustain good health and vitality. However, as we age, growth hormone releasing factor declines causing a decrease in the production and secretion of pituitary hGH. This often results in a growth hormone deficiency that can erode health, diminish vigor and vitality, and lead to a host of undesirable symptoms.

A Natural, Effective, Affordable Alternative

Traditionally, adult growth hormone deficiency (AGHD) has been treated by substituting natural hGH with recombinant human growth hormone (rhGH). Now, our breakthrough product, SERMORELIN GHRP2 offers a natural, effective, and affordable alternative to recombinant human growth hormone for those suffering the symptoms of age-related growth hormone deficiency.

Developed in 1998 by Serono Laboratories, Inc., the makers of Saizen hGH, FDA approved Sermorelin is the most natural and effective treatment for AGHD. As a releasing agent, SERMORELIN GHRP2 triggers the pituitary gland to produce your own natural growth hormone. Your body regulates the level and frequency of hGH release, so you don’t experience the side effects associated with injected rhGH.

No Off Cycles!

SERMORELIN GHRP2 requires no off-cycles. In fact, the longer you use it, the better your pituitary gland functions, more like it did when you were younger!! In addition, SERMORELIN GHRP2 can be used to re-stimulate the natural production of human growth hormone, making it a very effective off-cycle medication for those on an injected rhGH therapy program.

At our pharmacy, we’ve combined the pituitary-supporting effects of Sermorelin with the stimulating action of GHRP-2 (Growth Hormone Releasing Peptide). GHRP-2 stimulates the pituitary gland which causes an increase in growth hormone release. In addition to amplifying your GH releasing Hormone, GHRP-2 also acts to suppress other hormones that inhibit your body’s natural growth hormone secretion. GHRP-2 also supports your central nervous system by protecting neurons, as well as, increasing strength similar to the way certain steroids in the dihydrotestosterone family do.

Restore Your Health and Vitality!

Bottom line, restoring optimal growth hormone levels can sustain and promote youthful anatomy and physiology, thereby helping to restore the health and vitality often lost with age-related growth hormone deficiency. SERMORELIN GHRP2 not only provides the youth restoring benefits of hGH on body composition, it also helps maintain good pituitary health.

Men with erectile dysfunction should be examined for testosterone deficiency and the metabolic syndrome, because these conditions commonly occur together, a new study shows. The results will be presented at The Endocrine Society’s 90th Annual Meeting in San Francisco.

“Erectile dysfunction is a portal into men’s health,” said the study’s senior author, Aksam Yassin, MD, PhD, of the Clinic for Urology and Andrology of the Segeberger Clinics in Norderstedt, Germany. “It is becoming clear that obesity, diabetes, high blood pressure, cholesterol problems and erectile difficulties are intertwined, and a common denominator is testosterone deficiency.”

Yassin’s research, performed with scientists from The Netherlands, Germany and the United Arab Emirates, aimed to determine in men with erectile dysfunction (ED) the prevalence of hypogonadism, the scientific term for testosterone deficiency.

Over a two-year period the investigators studied 771 patients who sought treatment for ED. Their average age was 56. The patients received a comprehensive screening for low testosterone and indicators of the metabolic syndrome, a cluster of risk factors that increase the chances of developing heart and vascular disease and type 2 diabetes. Having three of the following five risk factors establishes the diagnosis of this syndrome: increased waist circumference (abdominal fat), low HDL (“good”) cholesterol, high triglycerides (fats in the blood), high blood pressure, and high blood sugar.

Among the 771 men, 18.3 percent of the men (141 men) had testosterone deficiency , which had previously been undetected, the authors found. The prevalence of hypogonadism in the general population of men age 45 and older is about 12 percent, Yassin said.

Of all the men in the study, 270 (35 percent) had type 1 or type 2 diabetes; in eight of the men, diabetes was a new diagnosis, according to study data. High blood pressure was found in 239 men (31 percent), and 12 of these men had been unaware of it. Among the 162 men (21 percent) who had dyslipidemia–abnormal cholesterol or triglycerides–nine of them had not previously been diagnosed. And 108 men, or 14 percent, had varying degrees of coronary heart disease. Five of them received this diagnosis for the first time, Yassin said.

Men with ED–especially older men–should therefore receive evaluation not only for ED but also for testosterone deficiency and any underlying signs of the metabolic syndrome, he advised.

Article Source: http://www.eurekalert.org/pub_releases/2008-06/tes-ltm061408.php

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/bostontestosterone
855-617-MEDS (6337)

BOSTON – In an effort to address widespread concerns related to testosterone deficiency (TD) and its treatment with testosterone therapy, a group of international experts has developed a set of resolutions and conclusions to provide clarity for physicians and patients. At a consensus conference held in Prague, Czech Republic last fall, the experts debated nine resolutions, with unanimous approval. The details of the conference were published today in a Mayo Clinic Proceedings report.

Much of the controversy surrounding testosterone therapy stems from intense media attention on recent reports suggesting increased heart-related risks associated with testosterone treatment. “The importance of this meeting was to set aside the various distortions and misinformation that have appeared regarding testosterone therapy and to establish what is scientifically true based on the best available evidence,” said Abraham Morgentaler, MD, chairman of the consensus conference. Morgentaler is the Director of Men’s Health Boston and an Associate Clinical Professor of Urology at Beth Israel Deaconess Medical Center and Harvard Medical School.

After examining the best available scientific evidence, Morgentaler and colleagues — who included experts with specialties in urology, endocrinology, diabetes, internal medicine, and basic science research — agreed on the following:

• TD is a well-established, clinically significant medical condition that negatively affects male sexuality, reproduction, general health and quality of life.
• Symptoms and signs of TD occur as a result of low levels of testosterone and may benefit from treatment regardless of whether there is an identified underlying origin.
• TD is a global public health concern.
• Testosterone therapy for men with TD is effective, rational, and evidence-based.
• There is no testosterone concentration threshold that reliably distinguishes those who will respond to treatment from those who will not.
• There is no scientific basis for any age-specific recommendations against the use of testosterone therapy in adult males.
• The evidence does not support increased risks of cardiovascular events with testosterone therapy.
• The evidence does not support increased risk of prostate cancer with testosterone therapy.
• The evidence supports a major research initiative to explore possible benefits of testosterone therapy for cardiometabolic disease, including diabetes.

“It will be surprising to those unfamiliar with the literature to learn how weak the evidence is supporting the alleged risks of cardiovascular disease and prostate cancer,” said Michael Zitzmann, MD, vice-chair of the conference and a Professor in the Centre for Reproductive Medicine and Andrology at the University of Muenster in Germany. “Indeed, there is substantial data suggesting there may actually be cardio-protective benefits of testosterone therapy.”

“The medical and scientific communities are still largely unaware of the major negative impact of testosterone deficiency on general health,” added co-author Abdulmaged Traish, PhD, a Professor of Urology at Boston University Medical Center. “The media-driven focus on unproven risks has obscured the known health risks of untreated testosterone deficiency: obesity, reduced bone mineral density, and increased mortality.”

Article Source: http://www.eurekalert.org/pub_releases/2016-06/bidm-ets062116.php

“The Greatest Health of Your Life”℠

Boston Testosterone Partners
National Testosterone Restoration for Men
Wellness & Preventative Medicine

http://www.BostonTestosterone.com

http://www.BTPWellness.com

http://www.facebook.com/bostontestosterone
855-617-MEDS (6337)